Table 1.
Overview of the Characteristics of the Patients Included in the Test and the Validation Sets
|
Clinicopathological Parameters |
Total |
Tumor Set |
|||
|
n |
Test Set,
n= 20 |
% |
Validation Set, n = 19 |
% |
|
| Mean age at diagnosis, y (SD) | 39 | 56.9 (±17.5) | 59.0 (±14.3) | ||
| Sex | |||||
| Male | 21 | 12 | 60 | 9 | 47 |
| Female | 18 | 8 | 40 | 10 | 53 |
| Eye | |||||
| Right | 22 | 10 | 50 | 12 | 63 |
| Left | 17 | 10 | 50 | 7 | 37 |
| Tumor diameter, mm (SD) | 39 | 13.5 (±4.7) | 13.1 (±3.0) | ||
| Tumor prominence, mm (SD) | 39 | 7.8 (±2.6) | 6.8 (±3.0) | ||
| Histopathologic cell type | |||||
| Spindle | 15 | 8 | 40 | 7 | 37 |
| Mixed/epithelioid | 24 | 12 | 60 | 12 | 63 |
| Ciliary body involvement | |||||
| No | 27 | 15 | 75 | 12 | 63 |
| Yes | 12 | 5 | 25 | 7 | 37 |
| Scleral ingrowth | |||||
| None | 5 | 2 | 10 | 3 | 16 |
| Superficial | 21 | 9 | 45 | 12 | 63 |
| Deep | 7 | 5 | 25 | 2 | 10.5 |
| Extrascleral | 6 | 4 | 20 | 2 | 10.5 |
| TNM stage | |||||
| Stage I | 4 | 0 | 0 | 4 | 21 |
| Stage IIA | 11 | 8 | 40 | 3 | 16 |
| Stage IIB | 13 | 7 | 35 | 6 | 32 |
| Stage IIIA | 10 | 4 | 20 | 6 | 32 |
| Stage IIIB | 0 | 0 | 0 | 0 | 0 |
| Stage IIIC | 1 | 1 | 5 | 0 | 0 |
| Stage IV | 0 | 0 | 0 | 0 | 0 |
| Metastasis | |||||
| No | 16 | 6 | 30 | 10 | 53 |
| Yes | 23 | 14 | 70 | 9 | 47 |
| Chromosome 3 status | |||||
| Disomy | 16 | 8 | 40 | 8 | 42 |
| Monosomy | 23 | 12 | 60 | 11 | 58 |
| Class | |||||
| 1 | ND | ND | ND | 10 | 53 |
| 2 | ND | ND | ND | 9 | 47 |
n
, number of tumors; SD, standard deviation; ND, not determined.